Another study stated that anti-PD-1/PD-L1 antibodies were ineffective in most patients, and response efficiencies were reported to be 20–30% when patients with various cancer types were treated with PD-1 antibodies [15,24,25]. This evidence concerns the gene CD274 and cancer.